Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in adult participants Pediatric population to be included in planned Phase 3 trial – expected to start in Q3 2022, subject to regulatory approval Saint-Herblain (France) and … Continue reading Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate